文摘
摘要目的:描述的阿仑单抗疗效和安全性活动名RRMS患者
背景:阿仑单抗的影响比在干扰素beta-1a 3 3期研究。它已通过欧洲药品局复发缓和多发性硬化(名RRMS)。考虑其安全性的法国国家权威健康(已经)限制其使用放射学和临床活动名RRMS目前,它的使用依赖于特殊授权。
设计/方法:我们回顾性的临床和放射学数据记录113病人阿仑单抗治疗自2015年1月。
结果:一百零四名患者(86名女性/男性27日)治疗(在治疗:平均年龄36.4岁)。除一名RRMS(1)可能进步形式。该病的发病平均年龄36岁(范围:13-54)。阿仑单抗的迹象是失败的治疗(76例,1%),PML风险(23%)和阿仑单抗作为第一线治疗1例。同时从女士开始治疗是11.1 + /−8.1年。患者平均eds是4.9(范围0 - 9.5)。在治疗的前一年,eds进步了0.76点和复发的平均为1.7。钆增强病变中发现67%的病人。在随访期间,73%的病人没有复发。意味着eds下降了0.24一年。输液相关反应被发现在69%的病人(主要是皮疹和头痛/发热)。 During the follow-up, 7% of the patients had infection whereas one each had immune thrombocytopenia and thyroid disorder.
结论:在法国阿仑单抗是给非常活跃的患者的疾病,其特征是平均eds 4.9和平均年复发率为1.7。阿仑单抗似乎是有效的和相对安全的经过1年的随访。
披露:ayrignac博士没有披露。Collongues博士没有披露。博士德Seze已收到个人活动与默克公司补偿,生原体,诺华,罗氏,Teva,局部反馈,Alexion,赛诺菲安万特Genzyme。博士德Seze已收到研究局部反馈和诺华公司的支持。Vermersch博士已经收到个人活动与生原体补偿,罗氏公司,默克公司Teva,赛诺菲安万特Genzyme, Almirall。Vermersch博士收到罗氏,研究支持生原体和赛诺菲安万特Genzyme。Biotti博士没有披露。Brassat博士已经收到个人活动与生原体补偿,赛诺菲安万特Genzyme, Teva,诺华,默克公司差旅费用和个人费用教育计划和董事会的参与。ayrignac博士没有披露。Vukusic博士已经收到个人活动与Bayer-Schering补偿,Idec, Genzyme,诺华,默克公司Serono,罗氏公司,赛诺菲-安万特和梯瓦制药公司。 Dr. Durand Dubief has nothing to disclose. Dr. Edan has nothing to disclose. Dr. Lepage has nothing to disclose. Dr. Deburghgraeve has nothing to disclose. Dr. Maillart has nothing to disclose. Dr. Papeix has nothing to disclose. Dr. Alla has nothing to disclose. Dr. Berger has received personal compensation for activities with Biogen-Idec and Novartis as a speaker. Dr. Bourre has nothing to disclose. Dr. Casez has received personal compensation for activities with Biogen Idec, Novartis Pharma, and Teva Pharma as a speaker. Dr. Pittion has nothing to disclose. Dr. Debouverie has received research support from Biogen, Sanofi Genzyme, EMD Serono, and Novartis. Dr. Theaudin has received personal compensation for activities with Novartis, Biogen, LFB, Bayer Schering Pharma, and Pfizer. Dr. Derache has received personal compensation for activities with EMD Serono, Biogen, and Novartis as a speaker. Dr. Defer has received personal compensation for activities with Biogen, Novartis, Sanofi Genzyme, Teva Pharmaceutical Industries Ltd., EMD Serono, and Guerbet. Dr. Defer has received research support fromNovartis and EMD Serono. Dr. Gout has nothing to disclose. Dr. Deschamps has nothing to disclose. Dr. Tourbah has received personal compensation for activities with Novartis, Sanofi-Aventis-Genzyme, Teva, Biogen-Idec, and Merck-Serono as a consultant, scientific advisory board member, or speaker. Dr. Zagnoli has nothing to disclose. Dr. Ruet has nothing to disclose. Dr. Ouallet has nothing to disclose. Dr. Brochet has received personal compensation for activities with for Biogen, Genzyme, Merck-Serono, Novartis and Roche for advisory boards. Dr. Manchon has nothing to disclose. Dr. Moreau has received personal compensation for activities with Biogen, Novartis, Roche, Sanofi Genzyme, and EMD Sérono. Dr. Moreau has received personal compensation in an editorial capacity for La Lettre du Neurolgue. Dr. Fromont has nothing to disclose. Dr. Clavelou has received personal compensation for activities with Sanofi Genzyme, Teva, Novartis, Almirall, and Biogen. Dr. Guennoc has nothing to disclose. Dr. Camdessanche has nothing to disclose. Dr. Carpentier has nothing to disclose. Dr. Coman has nothing to disclose. Dr. Audoin has nothing to disclose. Dr. Pelletier has nothing to disclose. Dr. Magy has nothing to disclose. Dr. Ciron has nothing to disclose. Dr. Wiertlevski has nothing to disclose. Dr. Laplaud has nothing to disclose. Dr. De Broucker has nothing to disclose. Dr. Lebrun Frenay has received personal compensation for activities with Genzyme, Novartis, Biogen, Merck, Teva, and Revue Neurologique as a member of the advisory board. Dr. Cohen has nothing to disclose. Dr. Labauge has nothing to disclose.
